Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 12, 1997, Pages 2531-2539

  Uno, Toshihiko ^a   Chen, Peter W ^a   Murray, Timothy G ^b   Podack, Eckhard R ^c   Ksander, Bruce R ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CD80; Costimulatory molecule; Episomal vector; Gene therapy; Ocular melanoma

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSFECTION; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; PLASMID; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTIGENS, CD80; BOVINE PAPILLOMAVIRUS 1; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; DNA, COMPLEMENTARY; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MELANOMA; PLASMIDS; POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 0030774295     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pardoll DM. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol. 1993;5:719-725.
2. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
3. + T cells against the wild type tumor: Correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
4. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumor in mice treated with interleukin-2 gene modified tumor cells. J Exp Med. 1993;177:1423-1434.
5. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or interferon. Proc Natl Acad Sci USA. 1993;90:2774-2778.
6. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
7. Blankenstein T, Rowley DA, Schreiber H. Cytokines and cancer: Experimental systems. Curr Opin Immunol. 1991;3:694-698.
8. Seigler HF, Darrow TL, Abdel-Wahab Z, Gangavalli R, Barber J. A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Human Gene Ther. 1994;5:761-777.
9. Nabel GJ, Chang AE, Nabel EG, et al. Immunotherapy for cancer by direct gene transfer into tumors. Human Gene Ther. 1994;5:57-77.
10. Berns AJ, Clift S, Cohen LK, et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Human Gene Ther. 1995;6:347-368.
11. Fenton RT, Sznol M, Luster DG, Taub DD, Longo DL. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. Human Gene Ther. 1995;6:87-106.
12. Sobol RE, Royston I, Fakhrai H, et al. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): A phase I study. Human Gene Ther. 1995;6:195-204.
13. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Ther. 1995;6:1607-1624.
14. Blaese M, Blankenstein T, Brenner M, et al. Vectors in cancer therapy: How will they deliver? Cancer Gene Ther. 1995;4:291-297.
15. Miller N, Vile R. Targeted vectors for gene therapy. FASEB J. 1995;9:190-199.
16. Brenner MK. Human somatic gene therapy: Progress and problems. J Int Med. 1995;237:229-239.
17. Hart I. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol. 1996; 23:154-158.
18. Ohe Y, Zhao D, Saijo N, Podack ER. Construction of a novel bovine papillomavirus vector without detectable transforming activity suitable for gene transfer. Human Gene Ther. 1995;6:325-333.
19. Cassleith PA, Podack ER. Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Human Gene Ther. 1995;6:369-383.
20. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331.
21. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA. 1990;87:5031-5035.
22. Linsley PS, Brady W, Urnes M. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-569.
23. Linsley PS, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Med. 1992;176:1595-1604.
24. Norton SD, Zuckerman L, Urdahl KB, Schefner R, Miller J, Jenkins MK The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol. 1992;149:1556-1561.
25. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J Exp Med. 1991;173:721-730.
26. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561-569.
27. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.
28. Chen C, Nabavi N. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity. 1994;1:147-154.
29. + T lymphocytes in the P815 tumor system in vitro. J Immunol. 1996;156:465-472.
30. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994; 54:6477-6483.
31. Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. Studies of tumor infiltrating lymphocytes from a human choroidal melanoma. Invest Ophthalmol Vis Sci. 1991;32:3198-3207.
32. Chen P, Murray TG, Salgaller ML, Ksander BR. Expression of MAGE genes in ocular melanoma cell lines. J Immunotherapy. 1997;20:265-275.
33. Selvakumar A, Mohanraj BK, Eddy RL, et al. Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7. Immunogenetics. 1992;36:175-181.
34. De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics. 1994;39:121-129.
35. Doyle K, ed. Protocols and Applications Guide, 3d ed. Madison: Promega Corporation; 1996:374.
36. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
37. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093-1102.
38. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995;182:1415-1421.